Post-hoc analysis of association of a circulating lipid panel with clinical outcomes in metastatic hormone-sensitive prostate cancer

PCPro is a plasma lipid panel associated with decreased overall survival in metastatic castration-resistant prostate cancer. Post-hoc analysis of the phase 3 ANZUP 1304 trial evaluated the association between PCPro and clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Participants with a positive PCPro status at baseline (13.4%) had significantly shorter OS (HR 1.81; p<0.0001) and clinical progression-free survival (HR 1.65; p<0.0001) compared to patients with baseline negative PCPro status. Enzalutamide compared to non-steroidal anti-androgen improved OS of PCPro-negative participants (HR 0.61; p<0.0001) but not OS of PCPro-positive participants (HR 1.10; p=0.69). The authors conclude that PCPro status is a prognostic biomarker and predictive of lack of OS benefit from enzalutamide compared to NSAA in mHSCP.